logo

For the Inventor, By the Inventor

Miaoli, Taiwan

Hsin-Wei Chen

This inventor holds 16 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignees: National Health Research Institutes, Academia Sinica, National Cheng-Kung University. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hsin-Wei Chen. Retrieved from https://idiyas.com/inventor/hsin-wei-chen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 

% Patents Active = 87.5

 

Average Co-Inventor Count = 4.5

ph-index = 3

Forward Citations = 21(Granted Patents)


Location History:

  • Zhunan Town, TW (2011 - 2014)
  • Zhunan, TW (2022)
  • Miaoli County, TW (2010 - 2023)

Company Filing History:

goldMedal15 out of 189 
 
National Health Research Institutes
 patents
silverMedal1 out of 728 
 
Academia Sinica
 patents
bronzeMedal1 out of 658 
 
National Cheng-Kung University
 patents
where one patent can have more than one assignee

Years Active: 2010-2026

Loading Chart...
Loading Chart...
16 patents (USPTO):Explore Patents
1. 12752003 - Lipidated FLIPr and uses thereof in vaccine (2026-10-06),
2. 11786587 - Composition of subunit dengue vaccine (2023-10-17),
3. 11266728 - Compositions and methods for enhancement of immune responses (2022-03-08),
4. 10995126 - Immunogenic peptide containing a b cell epitope of tumor associated antigen L6 (2021-05-04),
5. 10172945 - Sorbitan polyester conjugates for stabilizing water-in-oil emulsions and delivering controlled release of bioactive agents (2019-01-08),
6. 9415069 - Immunosuppressive cells and methods of making and using thereof (2016-08-16),
7. 8771990 - Method of producing lipidated polypeptides (2014-07-08),
8. 8658767 - Lipidated polyepitope vaccines (2014-02-25),
9. 8658176 - Lipidated tumor-associated antigens and immunotherapeutic compositions (2014-02-25),
10. 8466259 - Adjuvants (2013-06-18),
11. 8465756 - Immunogenic peptides of tumor associated antigen L6 and uses thereof in cancer therapy (2013-06-18),
12. 8444993 - Multi-phase emulsions based on amphiphilic block copolymers (2013-05-21),
13. 8426163 - [object Object] (2013-04-23),
14. 8287880 - Lipidated vaccine against dengue virus infection (2012-10-16),
15. 7981431 - Consensus dengue virus envelope protein domain III polypeptides (cED III) and their methods of use (2011-07-19),

Title: Hsin-Wei Chen: Innovator in Vaccine Development

Introduction

Hsin-Wei Chen is a prominent inventor based in Miaoli County, Taiwan. He has made significant contributions to the field of vaccine development, holding a total of 15 patents. His work focuses on enhancing immune responses and developing effective vaccines against diseases such as dengue fever.

Latest Patents

One of Hsin-Wei Chen's latest patents is the "Composition of subunit dengue vaccine." This invention relates to a composition that includes a fusion protein of conjugating or connecting delta C nonstructural protein 1 (NS1) to at least one polypeptide of NS3c and/or consensus envelope protein domain III (cEDIII). This innovative approach aims to provide better protection against dengue virus (DENV) challenges while alleviating associated pathological effects. Another notable patent is "Compositions and methods for enhancement of immune responses." This patent describes a pharmaceutical composition that includes an antigen fusion protein, which consists of an antigen and an antagonist of an Fc gamma receptor. The methods outlined in this patent focus on enhancing the immunogenicity of antigens and improving immune responses in subjects.

Career Highlights

Hsin-Wei Chen has worked with esteemed institutions such as the National Health Research Institutes and National Cheng Kung University. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field of immunology and vaccine technology.

Collaborations

Throughout his career, Hsin-Wei Chen has collaborated with notable colleagues, including Chih-Hsiang Leng and Pele Choi-Sing Chong. These partnerships have fostered innovation and advancement in vaccine research.

Conclusion

Hsin-Wei Chen is a distinguished inventor whose work in vaccine development has the potential to significantly impact public health. His innovative patents and collaborations highlight his commitment to enhancing immune responses and combating infectious diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…